Join EHA President prof. Konstanze Döhner from University Hospital Ulm in Germany who discusses the most recent developments in the management of young and fit patients with AML. Tune in to hear about the diagnostic workup, risk stratification, treatment and the evolving role of measurable residual disease (MRD) measurements in clinical decision making in this group of patients. Prof. Döhner also shares her thoughts on the future of the treatment landscape for AML.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Prof Konstanze Döhner
What did you think of this podcast? Share your opinions with us in this short feedback survey.
https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe